Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron

Leukemia

Volumn 29, Issue 1, 2015, Pages 188-195

  Visconte, V ^a   Avishai, N ^b   Mahfouz, R ^a   Tabarroki, A ^a   Cowen, J ^b   Sharghi Moshtaghin, R ^b   Hitomi, M ^c   Rogers, H J ^d   Hasrouni, E ^a   Phillips, J ^a   Sekeres, M A ^a,d   Heuer, A H ^b   Saunthararajah, Y ^a,d   Barnard, J ^d   Tiu, R V ^a,d  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b Case Western Reserve University   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC FERROCYANIDE; FERRITIN; IRON; PROTEIN VARIANT; REACTIVE OXYGEN METABOLITE; RHODAMINE B; SF3B1 PROTEIN; SLC25A37 PROTEIN; UNCLASSIFIED DRUG; CATION TRANSPORT PROTEIN; MFRN1 PROTEIN, HUMAN; MITOCHONDRIAL PROTEIN; PHOSPHOPROTEIN; SF3B1 PROTEIN, HUMAN; SMALL NUCLEAR RIBONUCLEOPROTEIN;

ARTICLE; BONE MARROW CELL; CELL ULTRASTRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; FLOW CYTOMETRY; GENE MUTATION; HUMAN; HUMAN CELL; INTRON; IRON BINDING CAPACITY; IRON METABOLISM; IRON OVERLOAD; MICROANALYSIS; MYELODYSPLASTIC SYNDROME; OXIDATIVE STRESS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; SOMATIC MUTATION; TRANSMISSION ELECTRON MICROSCOPY; CASE CONTROL STUDY; DNA SEQUENCE; GENETICS; METABOLISM; MITOCHONDRION; MUTATION; RNA SPLICING;

CASE-CONTROL STUDIES; CATION TRANSPORT PROTEINS; DNA DAMAGE; FLOW CYTOMETRY; HUMANS; INTRONS; IRON; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; MUTATION; MYELODYSPLASTIC SYNDROMES; PHOSPHOPROTEINS; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBONUCLEOPROTEIN, U2 SMALL NUCLEAR; RNA SPLICING; SEQUENCE ANALYSIS, DNA;

EID: 84920663583     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.170     Document Type: Article

References (39)

1. Bjorkman SE. Chronic refractory anemia with sideroblastic bone marrow; a study of four cases. Blood 1956; 11: 250-259.
2. Dorion RP, Alomari M, Wood GC. Predicting the presence or absence of ringed sideroblasts in patients suspected of having a myelodysplastic syndrome and increased iron stores: a simple observation. Leukemia 2001; 15: 1793-1795.
3. Pellagatti A, Cazzola M, Giagounidis AA, Malcovati L, Porta MG, Killick S et al. Gene expression profiles of CD34 + cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood 2006; 108: 337-345.
4. Boultwood J, Pellagatti A, Nikpour M, Pushkaran B, Fidler C, Cattan H et al. The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. PLoS One 2008; 3: e1970.
5. Cazzola M, Invernizzi R. Ring sideroblasts and sideroblastic anemias. Haematologica 2011; 96: 789-792.
6. Sato K, Torimoto Y, Hosoki T, Ikuta K, Takahashi H, Yamamoto M et al. Loss of ABCB7 gene: pathogenesis of mitochondrial iron accumulation in erythroblasts in refractory anemia with ringed sideroblast with isodicentric (X)(q13). Int J Hematol 2011; 93: 311-318.
7. Camaschella C, Campanella A, De Falco L, Boschetto L, Merlini R, Silvestri L et al. The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload. Blood 2007; 110: 1353-1358.
8. Caudill JS, Imran H, Porcher JC, Steensma DP. Congenital sideroblastic anemia associated with germline polymorphisms reducing expression of FECH. Haematologica 2008; 93: 1582-1584.
9. Visconte V, Makishima H, Jankowska A, Szpurka H, Traina F, Jerez A et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia 2012; 26: 542-545.
10. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011; 365: 1384-1395.
11. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478: 64-69.
12. Visconte V, Rogers HJ, Singh J, Barnard J, Bupathi M, Traina F et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood 2012; 120: 3173-3186.
13. Williams D, Carter CB. Transmission Electron Microscopy: A Textbook For Material Science. Chapter 39 (High-Energy Loss Spectra and Images). Plenum Press: New York, USA, 1996, pp 715-716.
14. Tan H, Verbeeck J, Abakumov A, Van Tendeloo G. Oxidation state and chemical shift investigation in transition metal oxides by EELS. Ultramicroscopy 2012; 116: 24-33.
15. Hirayama T, Okuda K, Nagasawa H. A highly selective turn-on fluorescent probe for iron(II) to visualize labile iron in living cells. Chem Sci 2013; 4: 1250-1256.
16. Traina F, Visconte V, Elson P, Tabarroki A, Jankowska AM, Hasrouni E et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia 2013; 28: 78-87.
17. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 2008; 5: 621-628.
18. Oshlack A, Robinson MD, Young MD. From RNA-seq reads to differential expression results. Genome Biol 2010; 11: 220.
19. Smyth G. Limma: linear models for microarray data. In Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W (eds.) Bioinformatics and Computational Biology Solutions using R and Bioconductor. Springer: New York, USA, 2005, pp 397-420.
20. Young MD, Wakefield MJ, Smyth GK, Oshlack A. Gene ontology analysis for RNA-seq: accounting for selection bias. Genome Biol 2010; 11: R14.
21. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 2013; 29: 15-21.
22. Glaus P, Honkela A, Rattray M. Identifying differentially expressed transcripts from RNA-seq data with biological variation. Bioinformatics 2012; 28: 1721-1728.
23. Barnard J, Rubin DB. Miscellanea. Small-sample degrees of freedom with multiple imputation. Biometrika 1999; 86: 948-955.
24. Wang Y, Langer NB, Shaw GC, Yang G, Li L, Kaplan J et al. Abnormal mitoferrin-1 expression in patients with erythropoietic protoporphyria. Exp Hematol 2011; 39: 784-794.
25. Garvie LAJ, Buseck PR. Ratios of ferrous to ferric iron from nanometre-sized areas in minerals. Nature 1998; 396: 667-670.
26. Visconte V, Mahfouz RZ, Tabarroki A, Hasrouni E, Rogers HJ, Saunthararajah Y et al. BCL-2 family of genes is a key regulator in the pathogenesis of SF3B1 mutant and wild type MDS with ring sideroblasts and represents a novel drug target in this disease. (ASH Annual Meeting). Blood 2013; 122: 263.
27. Chen W, Dailey HA, Paw BH. Ferrochelatase forms an oligomeric complex with mitoferrin-1 and Abcb10 for erythroid heme biosynthesis. Blood 2010; 116: 628-630.
28. Visconte V, Mahfouz RZ, Barnard J, Tabarroki A, Zhang L, Hasrouni E et al. Splicing factor 3b subunit 1 (SF3B1) mediates mitochondrial iron overload in myelodys-plastic syndromes with ring sideroblasts by alternative splicing of mitoferrin-1 (SLC25A37). (ASH Annual Meeting). Blood 2013; 122: 1555.
29. Visconte V, Makishima H, Maciejewski JP, Tiu RV. Emerging roles of the spliceo-somal machinery in myelodysplastic syndromes and other hematological disorders. Leukemia 2012; 26: 2447-2454.
30. Visconte V, Tabarroki A, Rogers HJ, Hasrouni E, Traina F, Makishima H et al. SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype. Haematologica 2013; 98: e105-e107.
31. Nikpour M, Scharenberg C, Liu A, Conte S, Karimi M, Mortera-Blanco T et al. The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts. Leukemia 2013; 27: 889-896.
32. Gattermann N. SF3B1 and the riddle of the ring sideroblast. Blood 2012; 120: 3167-3168.
33. Rademakers LH, Koningsberger JC, Sorber CW, Baart de la Faille H, Van Hattum J, Marx JJ. Accumulation of iron in erythroblasts of patients with erythropoietic protoporphyria. Eur J Clin Invest 1993; 23: 130-138.
34. Grasso JA, Myers TJ, Hines JD, Sullivan AL. Energy-dispersive X-ray analysis of the mitochondria of sideroblastic anaemia. Br J Haematol 1980; 46: 57-72.
35. Paradkar PN, Zumbrennen KB, Paw BH, Ward DM, Kaplan J. Regulation of mito-chondrial iron import through differential turnover of mitoferrin 1 and mitoferrin 2. Mol Cell Biol 2009; 29: 1007-1016.
36. Michael IP, Kurlender L, Memari N, Yousef GM, Du D, Grass L et al. Intron retention: a common splicing event within the human kallikrein gene family. Clin Chem 2005; 51: 506-515.
37. Galante PA, Sakabe NJ, Kirschbaum-Slager N, de Souza SJ. Detection and evaluation of intron retention events in the human transcriptome. RNA 2004; 10: 757-765.
38. Chen W, Paradkar PN, Li L, Pierce EL, Langer NB, Takahashi-Makise N et al. Abcb10 physically interacts with mitoferrin-1 (Slc25a37) to enhance its stability and function in the erythroid mitochondria. Proc Natl Acad Sci USA 2009; 106: 16263-16268.
39. Lane DJ, Richardson DR. Frataxin, a molecule of mystery: trading stability for function in its iron-binding site. Biochem J 2010; 426: e1-e3.